SMARCA2 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a, member 2) gene is mapped in human chromosome 9p24.3. SMARCA2 is also known as BRM(Brahma) and is an important catalytic component of the SWI/SNF (switch sucrose nonfermentable) chromatin remodeling complex.
Synonyms: Anti-BAF190; Anti-BRM; Anti-SNF2; Anti-SNF2L2; Anti-SNF2LA; Anti-SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2; Anti-SWI2; Anti-Sth1p; Anti-hBRM; Anti-hSNF2a
MDL Number: MFCD05665220
Storage: -20C
Application: Anti-SMARCA2 antibody produced in rabbit has been used in immunohistochemistry.
Biochem Physiol Actions: The components of SWI/SNF (switch sucrose nonfermentable) chromatin remodeling complex is often regarded as tumor suppressors. SMARCA2 along with SMARCA4 is an ATPase of the complex. SMARCA2 might be post-translationally silenced in many cancers. The loss of this gene expression might be as a result of epigenetic or post-translational modifications and may not be due to gene mutation in pancreatic and lung cancer cell lines. The expression of SMARCA2 is regulated by histone deacetylases HDAC3 (Histone deacetylases) and HDAC9 (Histone deacetylases), along with transcription factors MEF2D (myocyte enhancer factor 2D) and GATA3 (GATA binding protein 3). Loss of both SMARCA2 and SMARCA4 is specifically observed in small cell carcinoma of the ovary hypercalcaemic type.. The expression of SMARCA2 is retained by histone deacetylase inhibitor trichostatin A. Nicolaides-Baraitser syndrome involves SMARCA2 mutation.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC